Today: 17 June 2026

Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Rigetti Stock’s Quantum Roller Coaster: 3,000% Surge, Government Backing & Big Risks

Rigetti Stock’s Quantum Roller Coaster: 3,000% Surge, Government Backing & Big Risks

Rigetti Computing shares surged over 3,000% in the past year, peaking near $50 before retreating to the high-$30s after volatility tied to government funding talks. The company booked its first commercial quantum computer sales in September, worth $5.7 million. Q2 revenue fell 42% to $1.8 million, but Rigetti holds $572 million in cash. Analyst price targets vary widely, with recent downgrades citing valuation concerns.
3 November 2025
··
SoFi Stock Soars to New Highs After Record Earnings – Why Some Say It’s Just the Beginning

SoFi Stock Soars to New Highs After Record Earnings – Why Some Say It’s Just the Beginning

SoFi Technologies shares hit record highs near $31 after Q3 2025 revenue surged 38% to $950 million and net income more than doubled to $139 million. The company raised full-year guidance, now projecting 36% revenue growth. SoFi added 905,000 new members in the quarter, reaching 12.6 million. Wall Street remains cautious, with most analysts rating the stock Hold despite recent gains.
3 November 2025
···
Bitfarms (BITF) Skyrockets on AI Pivot – Bitcoin Miner’s 400% Rally and Future Outlook

Bitfarms (BITF) Skyrockets on AI Pivot – Bitcoin Miner’s 400% Rally and Future Outlook

Bitfarms Ltd. closed a $588 million convertible notes offering on October 21 to fund AI data center expansion, with notes convertible at $6.86 per share. Shares surged 428% in three months, reaching $4.20 in early November, and market cap stands at $2.3 billion. The company reported $245 million in trailing revenue and a net loss of $86 million. Bitfarms is shifting focus to HPC/AI amid rising mining difficulty.
3 November 2025
····
Plug Power’s High-Stakes Hydrogen Comeback: Stock Surge, CEO Shakeup & Big Deals Fuel 2025 Hopes

Plug Power’s High-Stakes Hydrogen Comeback: Stock Surge, CEO Shakeup & Big Deals Fuel 2025 Hopes

Plug Power shares traded near $2.70 on Nov. 3, 2025, rebounding from sub-$1 lows but still over 90% below 2021 highs. Q2 revenue rose 21% to $174 million, with gross margin improving to -31%. CEO Andy Marsh will step down by March 2026, succeeded by Jose Luis Crespo. The company signed a 2 GW electrolyzer deal with Allied Biofuels and expanded U.S. hydrogen and SAF partnerships.
3 November 2025
·
5 Dividend ETFs That Could Pay You for Life – One Could Turn $500/Month Into $680,000

5 Dividend ETFs That Could Pay You for Life – One Could Turn $500/Month Into $680,000

The Schwab U.S. Dividend Equity ETF (SCHD) yields about 3.9% annually with a 0.06% fee, while JPMorgan’s JEPI offers an 8.6% yield at a 0.35% expense ratio. As of early November 2025, SCHD trades near $26.50, VYM at $139, and JEPI at $57. Some niche ETFs show yields above 10%, but high payouts like TSLY’s 98% have come with steep losses, including a -34% one-year return.
3 November 2025
····
Record 2026 Tax Refund Surge Looms as New Tax Cuts Fuel a $50 Billion “Stimulus”

Record 2026 Tax Refund Surge Looms as New Tax Cuts Fuel a $50 Billion “Stimulus”

Americans are expected to receive tax refunds averaging $3,743—about $557 more than last year—when filing 2025 returns, due to retroactive tax cuts and unchanged IRS withholding tables. The changes, signed into law by President Trump in July, will deliver an estimated $50 billion in extra refunds, with most benefits going to higher earners. Economists warn the surge could temporarily boost consumer spending and inflation.
3 November 2025
·
Delisted Xbox 360 Games Suddenly Reappear – Backward Compatibility on the Horizon?

Delisted Xbox 360 Games Suddenly Reappear – Backward Compatibility on the Horizon?

Several previously delisted Xbox 360 games appeared on the Microsoft Store with a "Coming soon" label, despite no official announcement from Microsoft. The listings follow the July 2024 shutdown of the Xbox 360 marketplace. The move has fueled speculation about renewed backward compatibility efforts and possible emulator development. Licensing hurdles remain a barrier to reselling older titles.
3 November 2025
·
AI Chip Frenzy Sends Lam Research Soaring 117% – More Upside Ahead?

AI Chip Frenzy Sends Lam Research Soaring 117% – More Upside Ahead?

Lam Research shares have surged 117% year-to-date in 2025, far outpacing Nvidia and Broadcom. The company posted Q3 revenue of $5.32 billion, up about 28% year-over-year, and adjusted EPS jumped 46% to $1.26. Lam raised guidance for the next quarter, citing soaring demand for AI chipmaking equipment. CEO Tim Archer said AI data center investment is directly expanding Lam’s market.
3 November 2025
···
ClearPoint Neuro (CLPT) Stock Skyrockets on Brain Therapy Breakthroughs – 2025 Deep Dive

ClearPoint Neuro (CLPT) Stock Skyrockets on Brain Therapy Breakthroughs – 2025 Deep Dive

ClearPoint Neuro shares surged to the mid-$20s in November 2025 after hitting a 52-week high near $30, driven by heavy trading and recent product breakthroughs. The company reported Q2 revenue of $9.2 million, up 17% year-on-year, but remains unprofitable. Its neuro devices gained expanded FDA clearance and international approvals. Analysts maintain buy ratings with price targets averaging $29.
3 November 2025
·
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers said Oct. 29 it will offer clinician-supervised GLP-1 “microdose” plans using compounded semaglutide for metabolic health, priced at $1,200 for six months. The drugs, not FDA-approved, target patients with conditions like sleep apnea or high blood pressure. Medical experts warn safety data is limited and compounded versions carry risks. HIMS stock rose 2–3% after the announcement.
3 November 2025
···
CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?

CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?

CURE Pharmaceutical, now Avenir Wellness Solutions (AVRW), closed at $3.78 on Oct. 31, up 30.8% in one day and more than doubling over two weeks. The rally follows a settlement converting major debt to equity and anticipation of Nov. 18 earnings. The company rebranded in 2023 and focuses on wellness products. Technical signals warn of high volatility and potential pullback after the surge.
3 November 2025
·
Nocera (NCRA) Stock Skyrockets 36% on $300M Digital Asset Deal – Key Facts & Outlook

Nocera (NCRA) Stock Skyrockets 36% on $300M Digital Asset Deal – Key Facts & Outlook

Nocera, Inc. announced a private placement of up to $300 million in senior secured convertible notes to fund a stablecoin-based digital asset treasury and acquisitions. Shares surged as much as 36% pre-market on November 3, 2025, hitting a new 52-week high. The Taiwan-based firm, once focused on aquaculture, has shifted to an acquisition-driven model but remains unprofitable, with revenue down 29% in 2024.
3 November 2025
·
Dominion Energy’s Q3 Shocker: Data Center Boom and Offshore Wind Pay Off in Surging Profits

Dominion Energy’s Q3 Shocker: Data Center Boom and Offshore Wind Pay Off in Surging Profits

Dominion Energy reported Q3 2025 operating earnings of $1.06 per share, beating expectations, and GAAP net income rose to $1.0 billion from $934 million a year ago. Revenue jumped 15% to $4.53 billion, driven by strong power demand in Virginia and South Carolina. The company narrowed full-year guidance and is contracting to supply 47 GW of new data center capacity. Offshore wind project costs rose to $11.2 billion but remains on schedule.
3 November 2025
···
Biohaven Stock’s Wild Ride: Big Drops, Big Hopes as FDA Verdict Nears

Biohaven Stock’s Wild Ride: Big Drops, Big Hopes as FDA Verdict Nears

Biohaven Ltd. shares dropped over 20% in pre-market trading Nov. 3, falling to about $13.40 after closing at $17.20 on Oct. 31. The decline comes ahead of an FDA decision on troriluzole, expected in Q4 2025. The stock is down roughly 66% year-over-year, far underperforming biotech peers. Biohaven reported $408 million in cash mid-2025 but posted a $198 million net loss in Q2.
3 November 2025
·
Iovance Biotherapeutics (IOVA): TIL Cancer Breakthrough or Biotech Bust?

Iovance Biotherapeutics (IOVA): TIL Cancer Breakthrough or Biotech Bust?

Iovance shares traded near $2.00 on Nov. 3, 2025, with a market cap around $700 million after plunging 70% year-to-date. The company’s Amtagvi, the first FDA-approved TIL therapy for advanced melanoma, also secured Health Canada approval. Interim Phase 2 data showed a 25.6% response rate for lifileucel in advanced NSCLC. Iovance will hold its Q3 earnings call on Nov. 6.
3 November 2025
Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Phio Pharmaceuticals’ shares surged over 100% on November 3 after announcing positive Phase 1b results for its PH-762 skin cancer therapy, with one patient achieving full tumor clearance. No serious adverse effects were reported at any dose. The company, with a $12 million pre-rally market cap and no revenue, holds enough cash to fund operations into 2026 but will need more capital for larger trials. Analyst outlooks remain mixed.
3 November 2025
··
ON Semiconductor (ON) Stock Surges on Q3 Earnings Beat – Latest News, Financials, and Outlook

ON Semiconductor (ON) Stock Surges on Q3 Earnings Beat – Latest News, Financials, and Outlook

ON Semiconductor reported Q3 2025 net income of $255 million, or $0.63 per share, beating analyst estimates. Revenue reached $1.55 billion. The stock is down 10% year-to-date and 24% over 12 months, lagging sector gains. Analysts rate ON a “Moderate Buy,” with a $57–58 average price target, and expect a rebound in 2026 after a projected 42% EPS drop in 2025.
3 November 2025
··
UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure shares plunged nearly 65% to $23–24 midday Nov. 3 after the FDA ruled current Huntington’s trial data insufficient for approval, erasing billions in market value. The company had raised $345 million in September at $47.50/share following a surge on positive trial results. Q2 revenue was $5.3 million, with a net loss of $37.7 million. Cash reserves rose to about $550 million after the equity raise.
3 November 2025
··
1 … 56 57 58 59 60 … 148

Stock Market Today

  • Coffee Prices Surge to 5-Week Highs on Brazil Rain Delays and Supply Concerns
    June 16, 2026, 6:44 PM EDT. Coffee prices reached 5-week highs on Tuesday, with Arabica up 5.44% and Robusta rising 1.72%, driven by heavy rain forecasts in Brazil risking harvest delays. Brazil, the world's largest coffee producer, faces persistent rainfall across its coffee regions, supported by a forecast for moderate to heavy rain from Vaisala. ICE Arabica inventories fell to a 6.75-month low, reinforcing supply tightness. Meanwhile, concerns mount over a potential El Niño event, projected to be one of the strongest on record, threatening Brazil's 2026/27 coffee crop with delayed rains during critical flowering months. Despite a USDA forecast of a record 2026/27 Brazil coffee crop of 71.9 million bags, supply risks and tighter shipping conditions caused by the Strait of Hormuz closure bolster prices. Vietnam's rising coffee exports create pressure on Robusta prices, but supply challenges persist for global coffee markets.

Latest articles

Sadot Group drops 63% as Nasdaq deadline, deal filings shake investors

Sadot Group drops 63% as Nasdaq deadline, deal filings shake investors

17 June 2026
Sadot Group shares plunged 63.1% to $8.67 after a late-session volatility pause as investors weighed a looming June 22 Nasdaq delisting deadline tied to a stockholders’ equity shortfall, a $125.5 million Los Angeles property option paid with 17.71% of its stock, and ongoing liquidity and default risks.
Pfizer trades up with Rigel’s Veppanu deal done

Pfizer trades up with Rigel’s Veppanu deal done

17 June 2026
Pfizer shares edged up 0.15% to $26.04 after Rigel closed a Veppanu licensing deal with Arvinas and Pfizer, triggering a $35 million payment to Pfizer; the deal highlights ongoing investor focus on whether Pfizer’s oncology and obesity pipeline can offset COVID declines and looming patent losses, with analysts split on pipeline potential versus slow growth and patent pressure.
Go toTop